Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab ; volume:19 ; number:1 ; day:21 ; month:10 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (21.10.2019), 1-10, 12.2019
- Creator
-
Masuda, Ken
Shoji, Hirokazu
Nagashima, Kengo
Yamamoto, Shun
Ishikawa, Masashi
Imazeki, Hiroshi
Aoki, Masahiko
Miyamoto, Takahiro
Hirano, Hidekazu
Honma, Yoshitaka
Iwasa, Satoru
Okita, Natsuko
Takashima, Atsuo
Kato, Ken
Boku, Narikazu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-6150-y
- URN
-
urn:nbn:de:101:1-2020021522515025303144
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Masuda, Ken
- Shoji, Hirokazu
- Nagashima, Kengo
- Yamamoto, Shun
- Ishikawa, Masashi
- Imazeki, Hiroshi
- Aoki, Masahiko
- Miyamoto, Takahiro
- Hirano, Hidekazu
- Honma, Yoshitaka
- Iwasa, Satoru
- Okita, Natsuko
- Takashima, Atsuo
- Kato, Ken
- Boku, Narikazu
- SpringerLink (Online service)
Other Objects (12)
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab